Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia

2Citations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Three patients with pure red cell aplasia, with or without co-existing large granular lymphocytic leukaemia, who remained transfusion-dependent despite treatment with established firstline therapy, were treated with low-dose subcutaneous alemtuzumab 15 mg twice to thrice per week, for 3 to 4 weeks. The mean response time was 17 days compared with a response time of at least 61 days on standard first-line therapy. There were no serious side-effects and the mean duration of remission was 13 months. Low-dose subcutaneous alemtuzumab is a safe and effective treatment for pure red cell aplasia and further trials should be conducted to compare the long-term effectiveness of this treatment with conventional therapy.

Cite

CITATION STYLE

APA

Chow, J. K. W., & Chan, T. K. (2013). Low-dose subcutaneous alemtuzumab is a safe and effective treatment for chronic acquired pure red cell aplasia. Hong Kong Medical Journal, 19(6), 549–552. https://doi.org/10.12809/hkmj133798

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free